Skip to contentG
Gossamer Bio, Inc.
G
GOSSGossamer Bio, Inc. Q3 2024 · 10-Q
Revenue$9.48M$9.48M— vs Q3 2023 Net Income-$30.80M-$30.80MN/M vs Q3 2023 EPS Diluted-$0.14-$0.14N/M vs Q3 2023 Operating Income-$33,919,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gossamer Bio, Inc. · CIK 1728117 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$32,033,000N/M Margins · derivedOperating margin-357.8%
Net margin-324.9%
ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end